BlossomHill Therapeutics (NASDAQ:BLSM) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on shares of BlossomHill Therapeutics (NASDAQ:BLSM) in a report published on Tuesday morning, MarketBeat.com reports. The firm issued an overweight rating and a $28.00 price objective on the stock.

BLSM has been the topic of a number of other research reports. Wall Street Zen upgraded BlossomHill Therapeutics to a “hold” rating in a research report on Saturday, August 15th. Guggenheim started coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set a “buy” rating and a $30.00 price target for the company. Finally, HC Wainwright began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, BlossomHill Therapeutics has an average rating of “Buy” and an average price target of $32.20.

BlossomHill Therapeutics Price Performance

Shares of BLSM stock opened at $20.02 on Tuesday. BlossomHill Therapeutics has a fifty-two week low of $15.25 and a fifty-two week high of $20.61.

Insider Buying and Selling at BlossomHill Therapeutics

In related news, Director Orbimed Advisors Llc bought 625,000 shares of the stock in a transaction dated Monday, August 10th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the purchase, the director directly owned 2,714,279 shares of the company’s stock, valued at $43,428,464. This represents a 29.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bihua Chen bought 312,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the acquisition, the director owned 3,614,034 shares of the company’s stock, valued at $57,824,544. This trade represents a 9.47% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 1,573,900 shares of company stock worth $25,181,900.

Key BlossomHill Therapeutics News

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Multiple bullish analyst ratings: Leerink Partners initiated coverage with an “outperform” rating and a $36 price target, while HC Wainwright began coverage with a “buy” rating and a $35 target. Guggenheim also assigned a “buy” rating and a $30 target. These targets imply substantial upside from recent trading levels. BlossomHill Therapeutics coverage and analyst ratings
• Positive Sentiment: HC Wainwright expects improving losses: The firm projects fiscal 2026 EPS of $(3.71) and fiscal 2027 EPS of $(2.99), with quarterly losses narrowing from $(0.92) in the third quarter of 2026 to $(0.69) in the third quarter and fourth quarter of 2027. HC Wainwright reiterated its “buy” rating and $35 price objective. HC Wainwright BlossomHill Therapeutics estimates
• Positive Sentiment: Upcoming investor presentations: BlossomHill announced presentations at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference. The events could increase visibility for its oncology pipeline and provide potential updates on development programs. BlossomHill Therapeutics conference presentations
• Neutral Sentiment: Additional research coverage: Lifesci Capital and JPMorgan Chase & Co. reportedly initiated coverage of BLSM. The new coverage may broaden institutional awareness, although ratings and price targets were not provided in the available reports. Lifesci Capital initiates coverage JPMorgan initiates coverage

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.